Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon to Revise FY2022 Targets after Roivant Deal: President
Sumitomo Dainippon will revise its FY2022 targets under its ongoing five-year business plan in the wake of its strategic alliance with Roivant Sciences forged last year, President Hiroshi Nomura revealed on February 7. The revision will be made within FY2020…
To read the full story
Related Article
BUSINESS
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
- Sumitomo Regains DSP-0187 Rights as Jazz Calls Off Deal
February 27, 2026
- Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
- Daiichi Sankyo Chair Manabe to Step Down in June
February 27, 2026
- Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…